News

In the fourth quarter of 2008, the company recorded net revenue of $459.3 million compared to net revenue of $288.0 million in the fourth quarter of 2007, an

Celera reported net revenues of $47.3 million for the fourth quarter of calendar 2008 that ended December 27, 2008, compared to $40.3 million in the prior year quarter.

BioMarin and partner La Jolla Pharmaceutical have decided to stop the study, unblind the data and evaluate all of the clinical results including secondary endpoints such as systemic

Recent corporate highlights: Increased revenue from core products, which excludes therapeutic grade human serum albumin products, by 3%, or $0.2 million, in the first fiscal quarter of 2009

Vical had cash and investments of about $42 million at year-end 2008, including about $5 million invested in long-term auction rate securities. For the fourth quarter of 2008,

The Sandoz product is approved for the same range of indications as the reference product, Neupogen and offers patients comparable quality, safety and efficacy combined with greater cost-effectiveness.

Under the contract terms, OctoPlus will manufacture clinical trial material for Galapagos’s Phase II study of Nanocort. OctoPlus said that it has progressed the scale-up and robustness of

Oscient said that the employees affected by the restructuring will be offered severance benefits. The company is also eliminating approximately 25 positions which have been vacant. Following the

Forty-seven medical centers ordered the company’s Proxcelan seeds in the second quarter of fiscal 2009 compared to the 53 centers that ordered in the first quarter of fiscal